Fusion MRI TRUS prostate biopsy – pro
Fusion of MRI with ultrasound allows urologists to progress from blind, systematic biopsies to biopsies, which are mapped, targeted and tracked. A recent review in The Lancet concluded that using MP-MRI to triage men might allow 27% of patients avoid a primary biopsy and diagnosis of 5% fewer clinically insignificant cancers. If subsequent TRUS-biopsies were directed by MP-MRI findings, up to 18% more cases of clinically significant cancer might be detected compared with the standard pathway of TRUS-biopsy for all. MP-MRI, used as a triage test before first prostate biopsy, could reduce unnecessary biopsies by a quarter. MP-MRI can also reduce over-diagnosis of clinically insignificant prostate cancer and improve detection of clinically significant cancer.
Leonard Marks,a Shelena Young,a and Shyam Natarajanb, MRIultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. 2013 Jan; 23(1): 4350.
Hashim U Ahmed etal, Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet Volume 389, Issue 10071, 25 February3 March 2017, Pages 815-822